Former pharmaceutical CEO Martin Shkreli goes on trial starting Monday for federal securities fraud. Shkreli, who became known as “pharma bro,” came under widespread criticism for upping the price of the lifesaving drug Daraprim 5,000 percent. He is going on trial for something unrelated — prosecutors say that he operated a Ponzi-like scheme at two companies he ran.
Here & Now‘s Jeremy Hobson speaks with MSNBC’s Ali Velshi (@AliVelshi) about what’s expected in the trial.
Copyright 2021 NPR. To see more, visit https://www.npr.org.